Citadel Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$70.8M Sell
942,534
-1,192,102
-56% -$94.1M 0.01% 1072
2025
Q4
$169M Sell
2,134,636
-267,429
-11% -$20.1M 0.03% 561
2025
Q3
$157M Buy
2,402,065
+907,084
+61% +$44.3M 0.02% 590
2025
Q2
$59.1M Sell
1,494,981
-1,985,081
-57% -$65M 0.01% 1114
2025
Q1
$105M Buy
3,480,062
+1,314,146
+61% +$43M 0.02% 670
2024
Q4
$75.7M Buy
2,165,916
+1,764,765
+440% +$66M 0.01% 928
2024
Q3
$16.1M Sell
401,151
-225,882
-36% -$10.5M ﹤0.01% 2299
2024
Q2
$29.9M Buy
627,033
+549,003
+704% +$22.5M 0.01% 1609
2024
Q1
$3.38M Sell
78,030
-174,498
-69% -$8.32M ﹤0.01% 4583
2023
Q4
$12.8M Sell
252,528
-283,390
-53% -$13.6M ﹤0.01% 2530
2023
Q3
$24.3M Sell
535,918
-185,860
-26% -$7.67M 0.01% 1665
2023
Q2
$29.6M Buy
721,778
+570,255
+376% +$21.9M 0.01% 1486
2023
Q1
$5.42M Sell
151,523
-244,023
-62% -$9.16M ﹤0.01% 3680
2022
Q4
$14.9M Sell
395,546
-22,686
-5% -$954K ﹤0.01% 2298
2022
Q3
$18.5M Sell
418,232
-61,911
-13% -$2.61M ﹤0.01% 1961
2022
Q2
$17.8M Sell
480,143
-764,381
-61% -$28.8M ﹤0.01% 1976
2022
Q1
$46.1M Buy
1,244,524
+22,953
+2% +$751K 0.01% 1174
2021
Q4
$37.2M Buy
1,221,571
+171,714
+16% +$5.4M 0.01% 1420
2021
Q3
$35.2M Buy
1,049,857
+504,377
+92% +$19M 0.01% 1424
2021
Q2
$21.8M Buy
545,480
+375,631
+221% +$14.7M ﹤0.01% 1983
2021
Q1
$7.64M Sell
169,849
-455,141
-73% -$25.4M ﹤0.01% 3421
2020
Q4
$35.3M Sell
624,990
-1,344,523
-68% -$67M 0.01% 1245
2020
Q3
$93.5M Buy
1,969,513
+706,888
+56% +$39.3M 0.03% 495
2020
Q2
$74.4M Sell
1,262,625
-476,367
-27% -$26.5M 0.03% 554
2020
Q1
$82.2M Buy
1,738,992
+1,271,995
+272% +$70.9M 0.04% 419
2019
Q4
$28.2M Buy
466,997
+417,717
+848% +$24.9M 0.01% 1182
2019
Q3
$2.95M Sell
49,280
-533,549
-92% -$34.8M ﹤0.01% 3863
2019
Q2
$37.5M Buy
582,829
+427,750
+276% +$30.2M 0.02% 910
2019
Q1
$12.6M Buy
155,079
+50,125
+48% +$3.23M 0.01% 1803
2018
Q4
$5.67M Buy
104,954
+70,691
+206% +$3.61M ﹤0.01% 2610
2018
Q3
$1.77M Sell
34,263
-23,103
-40% -$1.09M ﹤0.01% 4609
2018
Q2
$2.39M Sell
57,366
-294,487
-84% -$13.1M ﹤0.01% 3823
2018
Q1
$15.5M Buy
351,853
+208,395
+145% +$10.6M 0.01% 1333
2017
Q4
$7.22M Buy
+143,458
New +$7.87M ﹤0.01% 2054
2017
Q3
Sell
-115,828
Closed -$6.07M 7754
2017
Q2
$5.89M Sell
115,828
-41
-0% -$1.91K 0.01% 1945
2017
Q1
$4.66M Buy
115,869
+107,464
+1,279% +$4.83M ﹤0.01% 2124
2016
Q4
$402K Sell
8,405
-339,858
-98% -$13.4M ﹤0.01% 5243
2016
Q3
$12.8M Buy
+348,263
New +$10.9M 0.01% 1158
2016
Q2
Sell
-192,216
Closed -$6.2M 7075
2016
Q1
$7.79M Buy
+192,216
New +$7.81M 0.01% 1389
2015
Q3
Sell
-312,428
Closed -$16.2M 9048
2015
Q2
$18M Buy
312,428
+219,578
+236% +$14M 0.02% 1069
2015
Q1
$5.91M Buy
92,850
+11,659
+14% +$791K 0.01% 1868
2014
Q4
$5.01M Sell
81,191
-63,078
-44% -$3.11M ﹤0.01% 1973
2014
Q3
$5.6M Buy
144,269
+82,077
+132% +$2.91M 0.01% 1884
2014
Q2
$2.14M Buy
62,192
+50,761
+444% +$1.6M ﹤0.01% 2667
2014
Q1
$494K Sell
11,431
-83,802
-88% -$4.06M ﹤0.01% 4359
2013
Q4
$3.79M Buy
+95,233
New +$3.39M ﹤0.01% 1909
2013
Q3
Sell
-7,515
Closed -$224K 6787
2013
Q2
$202K Buy
+7,515
New +$160K ﹤0.01% 4662

Other funds holding IONS

Citadel Advisors's IONS Position: Q1 2026 in Review

Citadel Advisors reduced its Ionis Pharmaceuticals (IONS) stake by 56% in Q1 2026, selling an estimated $94.1M and leaving 942,534 shares worth $70.8M. The position accounts for 0.01% of the portfolio, ranked #1072.

Citadel Advisors first reported a position in IONS in Q2 2013 and has held it in 47 quarters since. The position peaked at $169M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Citadel Advisors held 942,534 shares of Ionis Pharmaceuticals worth $70.8M as of Q1 2026.
  • Citadel Advisors sold 1,192,102 Ionis Pharmaceuticals shares in Q1 2026, an estimated $94.1M.
  • Ionis Pharmaceuticals made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1072 holding.
  • Citadel Advisors first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
  • Citadel Advisors's Ionis Pharmaceuticals position peaked at $169M in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.